N=1 Collaborative

Connecting researchers, industry, and patient groups to accelerate the development of individualized treatments.

Programs & Resources Driving Collaboration

Through targeted programs and resources, N1C helps researchers, clinicians, and patient communities work together to advance individualized therapies. Its offerings—from cross-sector workgroups to global registries—equip the field to solve challenges and move discoveries forward.

  • Connections: An open, multidisciplinary forum connecting researchers, clinicians, and families to share knowledge, surface challenges, and work together toward solutions.
  • Donated Resource Center: A collaborative hub for in-kind donations, mobilizing goods and services to advance individualized therapies for real patients with urgent needs. Contributions span disease areas, research stages, and institutions.
  • Workgroups: Eight cross-sector workgroups develop practical tools, consensus guidelines, and implementation playbooks to support individualized therapy development. Powered by volunteers across academic centers, biotech companies, clinical sites, and patient organizations, these groups ensure that outputs are grounded in diverse expertise and real-world needs.
  • Seminars and Podcasts: Community working sessions centered on shared challenges, evolving strategies, and the collective effort of advancing individualized therapies.
  • Annual Meeting: A global convening built around field updates, case-based discussions, and emerging strategies. Designed to help the community align, learn, and drive progress together.
  • Gene Registry: A community-sourced, global catalog of individualized therapy programs, including ASO, gene replacement, and gene editing efforts, designed to reduce duplication and enable coordination among investigators and potentially eligible patients.

N1C Resources

N1C advancing customized nucleic acid therapies through collaboration and data sharing

Consensus guidelines for assessing eligibility of pathogenic DNA variants for antisense oligonucleotide treatments

Consensus Guidelines for the Design and In Vitro Preclinical Efficacy Testing N-of-1 Exon Skipping Antisense Oligonucleotides

A framework for N-of-1 trials of individualized gene-targeted therapies for genetic dise

About N=1 Collaborative

The N=1 Collaborative (N1C) is a global nonprofit network fostering the development of interventional genetic medicines for patients with ultra-rare genetic conditions. N1C serves as an ecosystem enabler — convening stakeholders across academia, industry, and patient groups to share knowledge, coordinate efforts, and accelerate the translation of individualized therapies into an organized and accessible standard of care.

Step 1

Qualify & Sign Up

To sign up and qualify, you must have done one of the following within the past year:

  • Started a new lab
  • Expanded an existing lab
  • Moved your lab to a new location
  • Started a new company
  • Received a research grant

Step 2

Speak with Dedicated Experts

Driven by robust workflows, Danaher experts will help you personalize your lab by providing solution offerings to meet your needs.

Step 3

Prepare & Save

Discounts are available with further savings possible depending on your new launch requirements.

With no prior ASO experience, the Donated Resources Center gave us direct access to top-tier experts who supported both design and testing. It changed what was possible for our patient.

Dr. Alban Ziegler

Medical Geneticist

University Toulouse Hospital

Connect With Us to Accelerate Impact

Tap into a cross-sector partnership that fosters collaboration, speed discovery, and deliver practical solutions. Get started today.